Navigation Links
Dendreon Receives FDA Acknowledgement of Complete Response
Date:11/20/2009

pes of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including the FDA's actions with respect to the BLA and whether the FDA determines to convene an advisory committee to review the BLA; progress on the commercialization efforts for PROVENGE, including the expansion of Dendreon's manufacturing capacity and other necessary infrastructure; success in the hiring of additional personnel to support business growth and expansion; the outcome of pre-approval inspection of Dendreon's expanded manufacturing facility; and requisite receipt of FDA licensure for marketing of PROVENGE and the risk that additional capital could be needed in the future for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

SOURCE
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
2. Dendreon Completes Submission of Biologics License Application for PROVENGE
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
6. Dendreon Reports Second Quarter 2009 Financial Results
7. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
8. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
11. Dendreon Announces Closing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... CHICAGO , July 30, 2014  The Chicago ... the American Academy of Dermatology (Academy) in an effort ... the Chicago Bears will host free SPOT me™ skin ... August 2 at Soldier Field. SPOT me™ is ... men, about the dangers and risks of skin cancer, ...
(Date:7/30/2014)... Geneva, Switzerland (PRWEB) July 30, 2014 ... proven technologies for biologic drug discovery and mammalian cell ... SURE CHO-Mplus Libraries ™ will be presented at ... conference being held, September 8 – 10, 2014 ... Berkeley, California. , The following abstract will be ...
(Date:7/30/2014)... Albany, NewYork (PRWEB) July 30, 2014 ... population, the increase of personal health expenditure as ... government health care system, China diagnostic reagent industry ... reagents occupy over 90%. In 2013, Chinese in ... which RMB16.61 billion came from in vitro diagnostic ...
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
Breaking Biology Technology:Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2
... SAN DIEGO, Sept. 22 SoluLinK, Inc., a leader ... Catalyst, making conjugation at least 20 times faster than before ... , , Up to now, researchers, conjugation ... poor yields, poor quality and more labor and time consuming ...
... California and AMSTERDAM, September 22 ,Agendia, a world leader ... a US $23 million series E investment. The financing,round ... provided,approximately half of the funds. In addition, two independent ... while the remaining,capital was raised through Agendia,s existing investor ...
... , , CHICAGO, Sept. 22 ... healthcare. The average rate of compliance is only 50%. Noncompliance is ... annual cost of $100B. , , A recent ... by Leap of Faith Technologies, demonstrated a positive effect on compliance ...
Cached Biology Technology:SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100% Yields 2Agendia Raises US $23 Million in Series E Financing 2Medication Telemonitoring Improves Compliance and Behavior in NIH Study 2
(Date:7/30/2014)... research from Bjorn Brembs, professor of neurogenetics at the ... proof-of-concept figure allowing readers and reviewers to run the ... an important leap forward for scientific publishing, by demonstrating ... a scholarly output. , Figure 3 in fact doesn,t ... code to F1000Research , and the figure is ...
(Date:7/30/2014)... of major interest in neuroscience. A large number ... stages of Wallerian degeneration: transcription factor activation, immune ... expression responses in the distal segment of the ... differences in gene expression between the proximal and ... co-workers from Nantong University, China used microarrays to ...
(Date:7/30/2014)... cells types. Researchers would like to understand how to channel ... make up the organs and other structures of living organisms. ... sugars that dangle from proteins on surfaces of cells. , ... has created synthetic molecules that can stand in for the ... the process, they report in the Journal of the ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2
... research on aging and the life histories of diverse ... for individuals and tends to decrease lifespan rather than ... and Hynek Burda from the University of Duisburg-Essen shows ... true as well. , The authors, studying captive Zambian ...
... University of Florida scientists have found that people have ... personified today by a jawless, eel-like fish. , It ... different evolutionary road than almost all other backboned animals, ... terms of the genetics that govern their skeletal development, ...
... "evolutionary conversion" provides a modern-day snapshot of how life ... of the earliest primordial mix of RNA-like molecules-sometimes referred ... of RNA-based life (or the "RNA world") and eventually ... acids are large complex molecules that store and convey ...
Cached Biology News:UF scientists reveal ancient origin of vertebrate skeleton 2UF scientists reveal ancient origin of vertebrate skeleton 3'Accelerated evolution' converts RNA enzyme to DNA enzyme in vitro 2'Accelerated evolution' converts RNA enzyme to DNA enzyme in vitro 3
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Biology Products: